Abstract 311P
Background
Endometrial cancer (EC) is the most common gynecological malignancy worldwide. Therefore, early diagnosis of EC is critical. Routine endometrial cytology has low sensitivity and specificity. If there are few endometrial cells and there are no obvious signs of atypia, knowledge of additional diagnostic criteria will help identify pathological processes in the endometrium. The aim of the study was to evaluate the diagnostic significance of serum cytokines in patients with EC and uterine myoma (UM).
Methods
The blood serum of primary patients with stage I (initial) EC (n=42) according to FIGO was studied. The mean age of patients was 37-77 years, and patients with UM (n=20) (41-59 years). The control group included 30 practically healthy female donors (23-65 years). The level of IL1RA, IL17A (Cytokin, Russia), IL1β, 2, 4, 6, 8, 10, 18, TNFα, IFNγ and MCP- 1 (VBV, Russia) in pg/ml. The results were expressed as IQRQ1-Q3. The study was carried out in accordance with the requirements of the Ethics Commission of the Institute of ME&PhC of UlSU. Statistical analysis was performed using Jamovi 1.6.5.0.
Results
A significant increase in the level of IL1RA in the blood serum of patients at stage I EC at UM (p=0.002) and relative to control (p=0.001). The concentration of circulating IL6 was significantly increased at initial EC compared with UM (p=0.044). MCP-1 in the serum of patients with UM is reduced compared with the control group (p=0.013). At stage I EC, the level of MCP-1 in serum is significantly higher compared with control (p=0.012) and UM (p=0.005). The levels of other cytokines did not show significant differences with the control group in the presented model. In a univariate logistic regression analysis for the differential diagnosis between UM and EC, statistical significance was jointly demonstrated by IL1RA and serum IL6/MCP-1 The risk of EC increases with concomitantly elevated serum levels of IL1RA and IL6 (R2=0.82, χ2=30.5, p=0.001) with a probability of 96.2% (Spec.=0.80, Sens.=0.96), as well as with simultaneously elevated levels of IL1RA and MCP-1 (R2=0.75, χ2=26.4, р=0.001) with 88.5% probability (Spec.=0.80, Sens.=0.88).
Conclusions
Evaluation of the serum level of IL1RA, IL6, MCP-1 can be used in the differential diagnosis of EC and UM.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
193P - Impact of coronavirus disease 2019 on patients with unresectable hepatocellular carcinoma treated with atezolizumab/bevacizumab
Presenter: Hongjae Chon
Session: Poster Display
Resources:
Abstract
194P - Real-world outcomes of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus chemotherapy as first-line treatment in advanced gastric (G) or gastroesophageal junction (GEJ) cancer with PD-L1 CPS≤5
Presenter: Qi Xu
Session: Poster Display
Resources:
Abstract
195P - Ferroptosis signatures in pancreatic ductal adenocarcinomas and their role in patient survival: A translational unsupervised clustering analysis
Presenter: Quoc-Huy Trinh
Session: Poster Display
Resources:
Abstract
196P - Clinical significance of circulating CD8+ and CD4+ T cell proliferation in advanced gastric cancer receiving first-line chemotherapy
Presenter: In-Ho Kim
Session: Poster Display
Resources:
Abstract
197P - Treatment patterns and clinical outcomes of patients with unresectable advanced or metastatic (UAM) gastric/gastroesophageal junction adenocarcinoma (GA/GEJA) in China: A multicenter real-world study
Presenter: Yanqiao Zhang
Session: Poster Display
Resources:
Abstract
198P - Effectiveness of lenvatinib in patients with unresectable hepatocellular carcinoma: A multicenter observational study in Japan
Presenter: Namiki Izumi
Session: Poster Display
Resources:
Abstract
199P - Efficacy of endostar in combination with concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of esophagus: A randomized, open-label, phase II trial
Presenter: Yuexiao Qi
Session: Poster Display
Resources:
Abstract
200P - Prognosis of patients with hepatocellular carcinoma treated with transarterial chemoembolization: Development and validation of the ALFP score
Presenter: Baocuo Gong
Session: Poster Display
Resources:
Abstract
201P - A phase II study of serplulimab (a programmed death-1 inhibitor) with or without HLX04 (a bevacizumab biosimilar) for the treatment of advanced hepatocellular carcinoma
Presenter: Zhenggang Ren
Session: Poster Display
Resources:
Abstract
202P - Comparison of liver injury after transcatheter arterial chemoembolization and hepatic arterial infusion chemotherapy for intermediate and advanced hepatocellular carcinoma
Presenter: Yongru Chen
Session: Poster Display
Resources:
Abstract